Nanobots in Oncology, page-4

This is I have found using grok deeper search. This is just the conclusion but should answer to at least some of your questions

Conclusion

As of July 30, 2025, Nanobot Biosciences appears to be the most relevant company developing nanobots tested in mice via the bloodstream for cancer treatment, leveraging DNA origami technology to target and kill cancer cells while sparing healthy ones. Nanobots Therapeutics, while a significant player in nanobot-based cancer therapy, primarily focuses on bladder cancer with direct administration. Both companies represent the cutting edge of this field, with potential for future advancements in clinical applications.

Table: Summary of Key Companies and Their Technologies

Company	Founded	Location	Technology	Testing in Mice (Bloodstream)	Primary Focus	Stage (2025)
Nanobot Biosciences	2019	Arizona, USA (ASU spin-off)	DNA origami nanobots with thrombin	Yes, via bloodstream	General cancer treatment	Preclinical
Nanobots Therapeutics	2023	Barcelona, Spain (IBEC/ICREA)	Urease-powered nanobots	No, direct bladder administration	Bladder cancer	Preclinical

This table summarizes the key attributes of the identified companies, highlighting their relevance to the query and current development stage.